All Stories

  1. The gut-brain axis in diabetic neuropathy, cognitive impairment, and emotional disorders
  2. Epidemiological Trajectories and Quality of Care Disparities of MASLD in Asia, 1990–2023
  3. Global Trends and Projections in Chronic Kidney Disease Burden from Diabetes, Hypertension, and Glomerulonephritis: A Population-Based Study
  4. Microbiota-Targeted Modulation of the Gut–Kidney Axis in Diabetic Kidney Disease: Therapeutic Advances and Future Perspectives
  5. Sterol Regulatory Element-Binding Proteins and Metabolic Diseases: Mechanisms, Implications, and Therapeutic Strategies
  6. Association between cardiometabolic index and thyroid function: insights from NHANES
  7. The Role of Lactate Metabolism in Tumors
  8. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
  9. Autophagy–senescence interplay in kidney disease: mechanistic insights and therapeutic potential
  10. Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus
  11. Global burden of rheumatic vs non-rheumatic valvular heart disease, 1990–2021: a systematic analysis of the global burden of disease study
  12. Flavonoids in Metabolic Disease: A Narrative Review of Mechanisms and Therapeutic Potential
  13. Ribosome collisions and ZAKα activation: explores the therapeutic potential of metabolic diseases
  14. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study...
  15. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  16. METTL3-mediated m6A methylation: implications for diabetes pathogenesis and therapeutic potential
  17. The role and therapeutic potential of exosome-mediated microRNAs regulatory networks in diabetic kidney disease
  18. Editorial: Novel approaches to diet, exercise, and drugs in childhood obesity and metabolic diseases
  19. Efficacy and safety benefits of HR17031 , a fixed‐ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with ty...
  20. Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment
  21. Multimodal Neuroimaging of Brain Structure, Metabolism, and Function in Obesity: Current Landscape and Future Perspectives
  22. Editorial: Incretin-based therapies in the treatment of metabolic syndrome: expanding roles beyond weight management
  23. Global epidemiology and burden of type 2 diabetes in adults aged 55 and older: insights from 1990 to 2021
  24. Aging-Related Obesity: Unveiling Mitochondrial and Metabolic Dysfunction
  25. The global, regional, and national burden and attributable risk factors of Alzheimer's disease and other dementias, 1990-2021: A systematic analysis for the Global Burden of Disease Study
  26. Global epidemiology of type 1 diabetes in youth: 1990–2021 and projections to 2045
  27. Therapeutic Potential of Ginsenosides in the Treatment of Endocrine Diseases: Roles and Mechanisms
  28. Epigenetic regulation of nuclear receptors: Implications for endocrine-related diseases and therapeutic strategies
  29. Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990-2021 to 2045
  30. Nutritional Influences on Brown and Beige Adipocyte: Unraveling the Molecular Mechanisms and Metabolic Implications
  31. Associations between visceral adipose index, lipid accumulation products, and thyroid function parameters in U.S. Adults: analysis of NHANES data
  32. Exploring the Therapeutic Role of Pregnane X Receptor Activation in Acute Kidney Injury: Mechanisms and Clinical Implications
  33. Metabolic Dysfunction-Associated Steatotic Liver Disease and Chronic Kidney Disease: Unraveling Connections and Advancing Therapies
  34. Glycerophospholipid and Sphingosine- 1-phosphate Metabolism in Cardiovascular Disease: Mechanisms and Therapeutic Potential
  35. KRAS Mutations in Cancer
  36. Updated Insights on Childhood Diabetes Epidemiology 2019-2021 and Projections to 2045
  37. Revolutionizing public health through digital health technology
  38. Exploring heparin’s protective mechanism against AGEs induced endothelial injury
  39. Editorial: Metabolic diseases and healthy aging: prevention and public health policy based on risk factors
  40. The influence of perceived formative assessment on the learning autonomy of medical students: the chain mediating role of psychological empowerment and positive academic emotions
  41. Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation
  42. The complex link between the gut microbiome and obesity-associated metabolic disorders: Mechanisms and therapeutic opportunities
  43. Sestrin2 knockout exacerbates high-fat diet induced metabolic disorders and complications in female mice
  44. Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management
  45. Metagenomic and metabolomic analysis showing the adverse risk–benefit trade-off of the ketogenic diet
  46. Exploring the multi-targeting phytoestrogen potential of Calycosin for cancer treatment: A review
  47. The impact of the senescent microenvironment on tumorigenesis: Insights for cancer therapy
  48. Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial
  49. Epidemiology of 369 diseases and injuries attributable to 84 risk factors: 1990–2019 with 2040 projection
  50. Environmental toxicology of bisphenol A: Mechanistic insights and clinical implications on the neuroendocrine system
  51. 20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3‐mediated Wnt/β‑catenin signaling pathway
  52. Editorial: Potential pathophysiological mechanisms underlying the comorbidity of depression and macrovascular diseases
  53. Unraveling the role of the FHL family in cardiac diseases: Mechanisms, implications, and future directions
  54. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances
  55. Metabolic diseases and healthy aging: identifying environmental and behavioral risk factors and promoting public health
  56. BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
  57. Changing trends of the diseases burden attributable to high BMI in Asia from 1990 to 2019: results from the global burden of disease study 2019
  58. Secreted frizzled-related protein 5: A promising therapeutic target for metabolic diseases via regulation of Wnt signaling
  59. Secreted frizzled-related proteins: A promising therapeutic target for cancer therapy through Wnt signaling inhibition
  60. Role of dysfunctional peri-organ adipose tissue in metabolic disease
  61. Editorial: Incretin agonists in the treatment of obesity
  62. Mechanisms and efficacy of traditional Chinese herb monomers in diabetic kidney disease
  63. Global, Regional, and National Epidemiology of Diabetes in Children From 1990 to 2019
  64. Astrocytes in Post-Stroke Depression: Roles in Inflammation, Neurotransmission, and Neurotrophin Signaling
  65. Editorial: Clinical and genetic determinants of diabetes and complications
  66. Optimizing glycation control in diabetes: An integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules
  67. Editorial: The impact of adipose tissue dysfunction on cardiovascular and renal disease, Volume II
  68. Global, Regional, and National Burden of Pancreatic Cancer, 1990–2019: Results from the Global Burden of Disease Study 2019
  69. Editorial: Aging and chronic disease: public health challenge and education reform
  70. NTRK fusions in thyroid cancer: Pathology and clinical aspects
  71. Secular trends of epidemiologic patterns of chronic kidney disease over three decades: an updated analysis of the Global Burden of Disease Study 2019
  72. Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance (Review)
  73. Case report: Maturity-Onset Diabetes of the Young (MODY12) caused by ABCC8 gene mutations
  74. Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019
  75. Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice
  76. Identification of Potential Indicators for Survival in Patients with Thyroid Cancer Based on Expression of FAM3 Members
  77. Advances in Understanding the Roles of Mesenchymal Stem Cells in Lung Cancer
  78. Calycosin induces autophagy and apoptosis via Sestrin2/AMPK/mTOR in human papillary thyroid cancer cells
  79. Irisin protects against obesity-related chronic kidney disease by regulating perirenal adipose tissue function in obese mice
  80. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
  81. Glutaminolysis and CD4+ T-cell metabolism in autoimmunity: From pathogenesis to therapy prospects
  82. Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
  83. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
  84. COL1A1: A novel oncogenic gene and therapeutic target in malignancies
  85. The Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus
  86. Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis
  87. Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy
  88. Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development
  89. Utilizing Network Pharmacology and Molecular Docking Integrated Surface Plasmon Resonance Technology to Investigate the Potential Targets and Mechanisms of Tripterygium wilfordii against Pulmonary Artery Hypertension
  90. Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report
  91. Doctor of Public Health-Crisis Management and COVID-19 Prevention and Control: A Case Study in China
  92. Online Education Plight and Countermeasures for MBBS in Chinese Regional Medical Schools Based on the OBE Concept During COVID-19 Pandemic
  93. Editorial: The Impact of Adipose Tissue Dysfunction on Cardiovascular and Renal Disease
  94. Evodiamine induces ROS-Dependent cytotoxicity in human gastric cancer cells via TRPV1/Ca2+ pathway
  95. Comprehensive Analysis of Tumor Immune Microenvironment and Prognosis of m6A-Related lncRNAs in Lung Adenocarcinoma
  96. Association between serum Sestrin2 level and diabetic peripheral neuropathy in type 2 diabetic patients
  97. Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
  98. A paradoxical role for sestrin 2 protein in tumor suppression and tumorigenesis
  99. Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
  100. Identification of tRNA-derived Fragments and Their Potential Roles in Atherosclerosis
  101. Comprehensive overview of human serum albumin glycation in diabetes mellitus
  102. DL‑3‑n‑butylphthalide protects H9c2 cardiomyoblasts from ischemia/reperfusion injury by regulating HSP70 expression via PI3K/AKT pathway activation
  103. The analgesic efficacy of extracorporeal shock wave combined with percutaneous vertebroplasty in the treatment of osteoporotic thoracolumbar compression fractures in postmenopausal women
  104. Growth differentiation factor 11: a “rejuvenation factor” involved in regulation of age-related diseases?
  105. How to recognize and respond to viral re-positivity and disease relapse in patients with COVID-19
  106. Relationship between serum Dickkopf-1 and albuminuria in patients with type 2 diabetes
  107. Attaching clinical significance to COVID-19-associated diarrhea
  108. Identification of Potential Indicators for Survival in Patients With Thyroid Cancer Based on Mrna Expression Levels of Family With Sequence Similarity 3 Members
  109. Liraglutide improves obesity‐induced renal injury by alleviating uncoupling of the glomerular VEGF–NO axis in obese mice
  110. Epidemiology and clinical characteristics of 43 COVID-19 patients in Weifang, China
  111. Bioinformatic and biochemical findings disclosed anti-hepatic steatosis mechanism of calycosin
  112. SIRT1 agonism modulates cardiac NLRP3 inflammasome through pyruvate dehydrogenase during ischemia and reperfusion
  113. Novel insight into perirenal adipose tissue: A neglected adipose depot linking cardiovascular and chronic kidney disease
  114. Decreased shedding dipeptidyl peptidase 4 from membrane in Hashimoto's thyroiditis
  115. Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice
  116. Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway
  117. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
  118. Identification of Potential Indicators for Survival in Patients with Thyroid Cancer Based on mRNA Expression Levels of Family with Sequence Similarity 3 Members
  119. Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice
  120. A Meta-Analysis of Pregnancy Outcomes with Levothyroxine Treatment in Euthyroid Women with Thyroid Autoimmunity
  121. AMPK: a balancer of the renin–angiotensin system
  122. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
  123. AMPK: a therapeutic target of heart failure—not only metabolism regulation
  124. Screening of differentially expressed proteins from syncytiotrophoblast for severe early-onset preeclampsia in women with gestational diabetes mellitus using tandem mass tag quantitative proteomics
  125. Calycosin directly improves perivascular adipose tissue dysfunction by upregulating the adiponectin/AMPK/eNOS pathway in obese mice
  126. C1q/TNF-related protein 9 improves the anti-contractile effects of perivascular adipose tissue via the AMPK-eNOS pathway in diet-induced obese mice
  127. Irisin Improves Endothelial Dysfunction through Perivascular Adipose Tissue
  128. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice
  129. Irisin improves endothelial function in obese mice through the AMPK-eNOS pathway
  130. Renal protective effects of induction of haem oxygenase-1 combined with increased adiponectin on the glomerular vascular endothelial growth factor-nitric oxide axis in obese rats
  131. Induction of Haemeoxygenase-1 Directly Improves Endothelial Function in Isolated Aortas from Obese Rats through the Ampk-Pi3k/Akt-Enos Pathway
  132. Induction of Haemeoxygenase-1 Improves FFA-Induced Endothelial Dysfunction in Rat Aorta
  133. The relationship between circulating irisin levels and endothelial function in lean and obese subjects
  134. Protective effects of adiponectin on uncoupling of glomerular VEGF–NO axis in early streptozotocin-induced type 2 diabetic rats
  135. Perirenal fat associated with microalbuminuria in obese rats
  136. Effect of high free fatty acids on the anti-contractile response of perivascular adipose tissue in rat aorta
  137. High FFA levels related to microalbuminuria and uncoupling of VEGF-NO axis in obese rats
  138. Sonographic evaluation of para- and perirenal fat thickness is an independent predictor of early kidney damage in obese patients
  139. The effect of telomerase activity on vascular smooth muscle cell proliferation in type 2 diabetes in vivo and in vitro
  140. Serum Fetuin-A Levels Related with Microalbuminuria in Diet-Induced Obese Rats
  141. Time–Action Profile of an Oral Enteric Insulin Formulation in Healthy Chinese Volunteers
  142. Correlation of ultrasonographic measurement of intrarenal arterial resistance index with microalbuminuria in nonhypertensive, nondiabetic obese patients
  143. Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats
  144. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK–eNOS pathways
  145. High free fatty acids level related with cardiac dysfunction in obese rats
  146. Effect of Aspirin on the Expression of Hepatocyte NF-κB and Serum TNF-α in Streptozotocin-Induced Type 2 Diabetic Rats
  147. Effect of polysaccharides of theEuphoria longan(Lour.) Steud on inflammatory response induced by focal cerebral ischemia/reperfusion injury in rats